Tag:
STX-100
Latest Headlines
Latest Headlines
Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix
Biogen Idec ( $BIIB ) has scooped up a biotech very close to home. The Weston, MA-based biotech power has bought nearby Stromedix , whose lead fibrosis drug STX-100 was licensed from Biogen. The deal
Stromedix's STX-100 falls behind schedule
When Cambridge, MA-based Stromedix raised $25 million in 2008, CEO Michael Gilman said he hoped to have the company's lead drug, STX-100, well into Phase II trials by mid-2010. The drug, which was
